The HMG-CoA reductase inhibitor, simvastatin, has anti-tumorigenic effects in ovarian cancer cell lines and a genetically engineered serous ovarian cancer mouse model.

Stine, Jessica

147
The HMG-CoA reductase inhibitor, simvastatin, has anti-tumorigenic effects in ovarian cancer cell lines and a genetically engineered serous ovarian cancer mouse model.

Sunday, March 29, 2015: 3:05 PM

Salon C-D (Hilton Chicago)

J. E. Stine, X. Han, M. Schointuch, C. Zhou, T. Gilliam, K. H. Kim, P. A. Gehrig and V. L. Bae-Jump
University of North Carolina at Chapel Hill, Chapel Hill, NC

2015 Annual Meeting on Women's Cancer®

March 26 - 31, 2015

Navigation

147
The HMG-CoA reductase inhibitor, simvastatin, has anti-tumorigenic effects in ovarian cancer cell lines and a genetically engineered serous ovarian cancer mouse model.

147 The HMG-CoA reductase inhibitor, simvastatin, has anti-tumorigenic effects in ovarian cancer cell lines and a genetically engineered serous ovarian cancer mouse model.

147
The HMG-CoA reductase inhibitor, simvastatin, has anti-tumorigenic effects in ovarian cancer cell lines and a genetically engineered serous ovarian cancer mouse model.